These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 18561503)

  • 1. Management of venous thromboembolism in patients with cancer: role of dalteparin.
    Linkins LA
    Vasc Health Risk Manag; 2008; 4(2):279-87. PubMed ID: 18561503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
    Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
    Raskob GE; van Es N; Verhamme P; Carrier M; Di Nisio M; Garcia D; Grosso MA; Kakkar AK; Kovacs MJ; Mercuri MF; Meyer G; Segers A; Shi M; Wang TF; Yeo E; Zhang G; Zwicker JI; Weitz JI; Büller HR;
    N Engl J Med; 2018 Feb; 378(7):615-624. PubMed ID: 29231094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer.
    Cohen AT; Creeper KJ; Alikhan R; Er C; Connors JM; Huisman MV; Munoz A; Vescovo G; Bauersachs R; Ageno W; Agnelli G; Becattini C
    Thromb Haemost; 2024 Jul; 124(7):676-683. PubMed ID: 38196077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.
    Khorana AA; Francis CW; Kuderer NM; Carrier M; Ortel TL; Wun T; Rubens D; Hobbs S; Iyer R; Peterson D; Baran A; Kaproth-Joslin K; Lyman GH
    Thromb Res; 2017 Mar; 151():89-95. PubMed ID: 28139259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
    Dranitsaris G; Shane LG; Galanaud JP; Stemer G; Debourdeau P; Woodruff S
    Support Care Cancer; 2017 Jul; 25(7):2093-2102. PubMed ID: 28204995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
    Francis CW; Kessler CM; Goldhaber SZ; Kovacs MJ; Monreal M; Huisman MV; Bergqvist D; Turpie AG; Ortel TL; Spyropoulos AC; Pabinger I; Kakkar AK
    J Thromb Haemost; 2015 Jun; 13(6):1028-35. PubMed ID: 25827941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
    Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
    Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.
    Dranitsaris G; Shane L; Burgers L; Woodruff S
    Clin Appl Thromb Hemost; 2016 Oct; 22(7):617-26. PubMed ID: 27436663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
    Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
    Arce-Huamani MA; Barboza JJ; Martínez-Herrera JF; Torres-Roman JS; Maguiña JL
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893585
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of cancer-associated venous thromboembolism].
    Di Nisio M
    G Ital Cardiol (Rome); 2018 Sep; 19(9 Suppl 1):7S-12S. PubMed ID: 30284557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism.
    Damle B; Jen F; Sherman N; Jani D; Sweeney K
    J Clin Pharmacol; 2021 Feb; 61(2):172-180. PubMed ID: 32827160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
    N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Jun; (6):CD006649. PubMed ID: 21678360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006649. PubMed ID: 21328285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Apr; (4):CD006649. PubMed ID: 21491395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits.
    Dudley RR; Aziz I; Bonnici A; Saluja RS; Lamoureux J; Kalmovitch B; Gursahaney A; Razek T; Maleki M; Marcoux J
    J Neurotrauma; 2010 Dec; 27(12):2165-72. PubMed ID: 20939698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Kahale L; Neumann I; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2014 Jun; (6):CD006649. PubMed ID: 24945634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.
    Woodruff S; Feugère G; Abreu P; Heissler J; Ruiz MT; Jen F
    J Thromb Thrombolysis; 2016 Nov; 42(4):494-504. PubMed ID: 27344439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.